Long-term Outcomes of Prostate Cancer Screening

Long-term Outcomes of Prostate Cancer Screening Using PSA, Biomarkers and MRI: The STHLM3MRI Trial

This study is an expansion of the screening-by-invitation STHLM3MRI trial for detection of prostate cancer. In summary, we assess longterm outcomes (prostate cancer mortality, incidence and resource use) in men (i) invited and randomized to a screening program using PSA, a biomarker test and MRI; (ii) invited and randomized to a single PSA test with prostate biopsies followed by opportunistic testing and (iii) population controls. Mortality is verified through register data, disease verification is made through in-study biopsy results and registry data.

Eligible participants:

-Men eligible for the longterm f/u-study arms (experimental and control) are participants in the STHLM3MRI trial.

Inclusion Criteria:

• Men age 50-74 years without prior diagnosis of prostate cancer (ICD-9 C61).
• Permanent postal address in Stockholm
• Not a previous participant in the Stockholm3 study (2012-2014)

Exclusion Criteria:

• Severe illnesses such as metastatic cancers, severe cardio-vascular disease or dementia
• Contraindications for magnetic resonance imaging (MRI) eg pacemaker, magnetic cerebral clips, cochlear implants or severe claustrophobia.
• Men with a previous prostate biopsy the preceding 60 days before invitation.